• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

    3/18/24 7:00:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGEN alert in real time by email

    Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James "Jim" Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial. Oragenics' lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion. ONP-002 is a new chemical entity (NCE) designed to target the brain through delivery into the nasal cavity and onward to the brain. A 40-patient Phase I study was completed and showed the drug to be safe and well-tolerated.

    In the recent past, Dr. Kelly served as the Executive Director of the Marcus Institute for Brain Health (MIBH) and Professor of Neurology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. The MIBH specialized treatment program is funded by the Marcus Foundation to care for US military veterans with persistent symptoms of TBI. Dr. Kelly was also National Director of the Avalon Action Alliance TBI Programs for which the MIBH serves as the clinical coordinating center.

    "I am excited to join Oragenics as its Chief Medical Officer at such an important and pivotal time in the drug development process. I have been involved with the drug for many years now and look forward to testing the drug and showing it can improve patient outcomes in our upcoming Phase II clinical trials," said Dr. Kelly.

    Prior to these recent positions, Dr. Kelly was the Director of the National Intrepid Center of Excellence (NICoE) at Walter Reed National Military Medical Center in Bethesda, MD. As its founding Director, he led the creation of an innovative interdisciplinary team of healthcare professionals who blended high-tech diagnosis and treatment with complementary and alternative medical interventions in a holistic, integrative approach to the care of US military personnel with the complex combination of TBI and psychological conditions, such as post-traumatic stress, depression, and anxiety. In this role, Dr. Kelly was frequently called upon by leaders of the Military Health System at the Pentagon, the US Congress, the Department of Veterans Affairs, and numerous military facilities in the continental US and abroad. Dr. Kelly has interacted with the FDA and clinical trials for brain injury throughout his esteemed career. He is a strong advocate for treatments in the acute phase of brain injury and understands the value of protecting the brain early on from inflammation, swelling and oxidative stress to gain better clinical outcomes.

    "We are fortunate to have such an esteemed neurologist as Dr. Kelly join our team in this important role at Oragenics. Dr. Kelly is recognized as a leading expert in concussion and other brain injuries and we are fortunate to have him lead our drug trials going forward. We are currently completing the drug manufacturing and formulation at GMP facilities to ensure the integrity of the drug before and during the trials, and we look forward to completing this work in the short-term and getting the Phase II trial underway," stated Michael Redmond, President of Oragenics.

    In preclinical animal models, the drug has been shown to acutely improve molecular and behavioral outcomes following brain injury. In addition, intranasal delivery of the drug as a nanoparticle has been shown to enhance brain exposure and metabolism in animals. "Our Phase I human study has shown ONP-002 to be well tolerated in humans. Our mission now is to show that the ONP-002 brain protective mechanisms in animals translates to humans. Our Phase II study is designed to establish time to first dose, relationships between drug application and blood biomarkers, and the evaluation of clinical endpoints to determine improved in patient outcomes, " said Dr. Kelly.

    Concussion is an unmet medical need. There is an estimated 69 million concussions annually reported worldwide. Common causes of concussion include falls, motor vehicle accidents, and contact sports. Other neurological disorders including Alzheimer's Disease, Parkinson's Disease and Chronic Traumatic Encephalopathy (CTE) have been linked to concussion. Post concussion syndrome is linked to long term disability and occurs in as high as 20% of concussed patients.

    Forward-Looking Statements

    This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the ability of the Company to timely and successfully undertake the Phase II clinical trial using its novel drug - device combination for the treatment of mild Traumatic Brain Injury. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to: the Company's ability to advance the development of its product candidates, including the neurology assets, under the timelines and in accord with the milestones it projects; the Company's ability to retain its key employees and independent contractors necessary to continue to develop its product candidates and in particular ONP-002 and the availability of those key employees and independent contractors; the Company's ability to raise capital and obtain funding, non-dilutive or otherwise, for the development of its product candidates; the Company's expectations as to the outcome of the Phase II clinical trial and the potential benefits, activity, effectiveness and safety of its product candidates including as to administration, transmission, manufacturing, storage and distribution; and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth is as of the date hereof unless otherwise indicated. You should consider these factors in evaluating the forward-looking statements included and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

    Released March 18, 2024

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240318916780/en/

    Get the next $OGEN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OGEN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OGEN
    SEC Filings

    See more
    • Oragenics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - ORAGENICS INC (0001174940) (Filer)

      7/2/25 4:30:18 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Oragenics Inc.

      424B5 - ORAGENICS INC (0001174940) (Filer)

      7/2/25 8:15:24 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Oragenics Inc.

      EFFECT - ORAGENICS INC (0001174940) (Filer)

      7/1/25 12:15:12 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oragenics Completes Approximately $16.5 Million Offering

      SARASOTA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal therapeutics for neurological disorders, today announced the successful closing of its previously announced public offering of Series H Convertible Preferred Stock and Warrants. The Company secured total gross proceeds of approximately $16.5 million. As part of the transaction, Oragenics issued 660,000 shares of its Series H Convertible Preferred Stock, no par value, together with Warrants to purchase up to 660,000 additional shares of Series H Convertible Preferred Stock. Each unit, consisting of one share of Preferred Stock and one Warrant, was sold

      7/2/25 4:15:00 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

      SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company's Series H Convertible Preferred Stock ("Preferred Stock"), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an exercise price of $25.00 per share (the "Warrants"). The combined public Offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00 (the "Offering"). The Preferr

      7/1/25 8:31:01 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

      SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15–18, 2025, in Philadelphia, Pennsylvania. These back-to-back events represent key opportunities for Oragenics to highlight its lead candidate, ONP-002, an intranasal neurosteroid in development for the treatment of concussion (mild

      6/10/25 8:30:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman Sachs initiated coverage on Oragenics with a new price target

      Goldman Sachs initiated coverage of Oragenics with a rating of Neutral and set a new price target of $52.00

      6/3/21 6:23:39 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Odyssey Health, Inc. sold $30,407 worth of Common Stock - OGEN (7,044 units at $4.32), closing all direct ownership in the company (SEC Form 4)

      4 - ORAGENICS INC (0001174940) (Issuer)

      6/18/25 5:10:06 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Odyssey Health, Inc. sold $43,600 worth of Common Stock - OGEN (10,000 units at $4.36), decreasing direct ownership by 59% to 7,044 units (SEC Form 4)

      4 - ORAGENICS INC (0001174940) (Issuer)

      6/16/25 6:01:26 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Odyssey Health, Inc. claimed ownership of 249,623 units of Series F Preferred Stock and claimed ownership of 17,044 shares (SEC Form 3)

      3 - ORAGENICS INC (0001174940) (Issuer)

      6/16/25 5:54:50 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health

      SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health. The Leigh Steinberg Foundation is dedicated to advancing brain health by supporting research, raising awareness, and driving actionable solutions for those affected by concussions and traumatic brain injuries (TBI). Dr. Kelly's appointment to the Medical Board reflects his leadership in brain injury resear

      2/24/25 8:30:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

      SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

      1/21/25 8:15:00 AM ET
      $MEDS
      $OGEN
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Oragenics Appoints William "Frank" Peacock MD as Chief Clinical Officer

      SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William "Frank" Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department ("ED"). Oragenics' lead drug candidate, ONP-002, is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (mTBI), commonly known as concussion, in the field and emergency departments. ONP-002 is a new chemical entity (NCE) designed to target the brain through deliver

      5/22/24 8:00:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Financials

    Live finance-specific insights

    See more
    • Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

      TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Offic

      2/12/21 8:00:00 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

      SC 13G/A - ORAGENICS INC (0001174940) (Subject)

      11/14/24 7:29:57 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

      SC 13G/A - ORAGENICS INC (0001174940) (Subject)

      11/14/24 3:59:00 PM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Oragenics Inc.

      SC 13G - ORAGENICS INC (0001174940) (Subject)

      9/11/24 7:45:36 AM ET
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care